search
Back to results

JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme

Primary Purpose

Cerebrovascular Accident

Status
Completed
Phase
Phase 3
Locations
Japan
Study Type
Interventional
Intervention
Aggrenox capsule
Acetylsalicylic Acid (ASA)
Sponsored by
Boehringer Ingelheim
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Cerebrovascular Accident

Eligibility Criteria

50 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patients with a diagnosis of cerebral infarction (excluding cardiogenic cerebral embolism) who meet the diagnostic criteria based on the National Institute of Neurological Disorders and Stroke (NINDS) ad hoc committee's classification of cerebrovascular disease III. Patients who have had an onset of cerebral infarction, the time of which is known, between 1 week and 6 months before the time of enrolment (including first and recurrent cerebral infarctions) Patients who are 50 years or older Patients whose neurological signs and symptoms are considered to be stable by the investigator or sub-investigator Patients with a finding corresponding to the responsible focus confirmed by head X-ray computerised tomography (CT) or magnetic resonance imaging (MRI) Patients who have at least two of the following risk factors: diabetes hypertension (systolic blood pressure is 140 mmHg or higher or diastolic blood pressure is 90 mmHg or higher) or under treatment of hypertension smoker (at the time of onset of cerebral infarction) obesity (Body mass index (BMI) is more than 25 kg/m2) previous vascular disease (stroke, acute myocardial infarction or peripheral arterial disease before the onset of cerebral infarction) end-organ damage (retinopathy, left ventricular hypertrophy (LVH) or microalbuminuria) hyperlipidaemia Exclusion Criteria: Patients with a diagnosis of brain disorders with a bleeding risk such as brain haemorrhage, subarachnoid haemorrhage, cerebral arteriovenous (AV) malformation, cerebral AV aneurysms and brain tumours Patients with complications of cardiac disorders (atrial fibrillation, mitral valve stenosis, severe cardiac valve disorders) that may provide an embolic source for cerebral embolism Patients having had acute coronary syndromes (acute myocardial infarction, unstable angina) within 6 months after enrolment in this study Patient with hypersensitivity to dipyridamole preparations Patients with a history of drug allergy to acetylsalicylic acid (ASA) or aspirin asthma Patients with a history of peptic ulcer Patients having undergone arterial reconstruction after development of cerebral infarction Patients with very severe impairment (4 or 5 on Modified Rankin Scale) Patients with bleeding or bleeding tendencies (haemophilia, haemorrhage urinary tract, vitreous haemorrhage, etc.) Patients with severe hypertension (systolic blood pressure is 180 mmHg or higher or diastolic blood pressure is 110 mmHg or higher) Patients with complications such as serious cardiac, renal and hepatic disorders Patients with a malignant tumour or having had a tumour treatment in the past 5 years Women who are or may be pregnant or lactating women

Sites / Locations

  • 9.178.060 Boehringer Ingelheim Investigational Site
  • 9.178.017 Boehringer Ingelheim Investigational Site
  • 9.178.032 Boehringer Ingelheim Investigational Site
  • 9.178.074 Boehringer Ingelheim Investigational Site
  • 9.178.062 Boehringer Ingelheim Investigational Site
  • 9.178.064 Boehringer Ingelheim Investigational Site
  • 9.178.097 Boehringer Ingelheim Investigational Site
  • 9.178.056 Boehringer Ingelheim Investigational Site
  • 9.178.067 Boehringer Ingelheim Investigational Site
  • 9.178.117 Boehringer Ingelheim Investigational Site
  • 9.178.166 Boehringer Ingelheim Investigational Site
  • 9.178.089 Boehringer Ingelheim Investigational Site
  • 9.178.054 Boehringer Ingelheim Investigational Site
  • 9.178.133 Boehringer Ingelheim Investigational Site
  • 9.178.030 Boehringer Ingelheim Investigational Site
  • 9.178.077 Boehringer Ingelheim Investigational Site
  • 9.178.002 Boehringer Ingelheim Investigational Site
  • 9.178.119 Boehringer Ingelheim Investigational Site
  • 9.178.161 Boehringer Ingelheim Investigational Site
  • 9.178.112 Boehringer Ingelheim Investigational Site
  • 9.178.098 Boehringer Ingelheim Investigational Site
  • 9.178.046 Boehringer Ingelheim Investigational Site
  • 9.178.145 Boehringer Ingelheim Investigational Site
  • 9.178.099 Boehringer Ingelheim Investigational Site
  • 9.178.165 Boehringer Ingelheim Investigational Site
  • 9.178.072 Boehringer Ingelheim Investigational Site
  • 9.178.081 Boehringer Ingelheim Investigational Site
  • 9.178.024 Boehringer Ingelheim Investigational Site
  • 9.178.136 Boehringer Ingelheim Investigational Site
  • 9.178.082 Boehringer Ingelheim Investigational Site
  • 9.178.118 Boehringer Ingelheim Investigational Site
  • 9.178.052 Boehringer Ingelheim Investigational Site
  • 9.178.138 Boehringer Ingelheim Investigational Site
  • 9.178.169 Boehringer Ingelheim Investigational Site
  • 9.178.001 Boehringer Ingelheim Investigational Site
  • 9.178.026 Boehringer Ingelheim Investigational Site
  • 9.178.163 Boehringer Ingelheim Investigational Site
  • 9.178.120 Boehringer Ingelheim Investigational Site
  • 9.178.028 Boehringer Ingelheim Investigational Site
  • 9.178.140 Boehringer Ingelheim Investigational Site
  • 9.178.122 Boehringer Ingelheim Investigational Site
  • 9.178.101 Boehringer Ingelheim Investigational Site
  • 9.178.093 Boehringer Ingelheim Investigational Site
  • 9.178.153 Boehringer Ingelheim Investigational Site
  • 9.178.005 Boehringer Ingelheim Investigational Site
  • 9.178.079 Boehringer Ingelheim Investigational Site
  • 9.178.143 Boehringer Ingelheim Investigational Site
  • 9.178.019 Boehringer Ingelheim Investigational Site
  • 9.178.129 Boehringer Ingelheim Investigational Site
  • 9.178.011 Boehringer Ingelheim Investigational Site
  • 9.178.045 Boehringer Ingelheim Investigational Site
  • 9.178.031 Boehringer Ingelheim Investigational Site
  • 9.178.135 Boehringer Ingelheim Investigational Site
  • 9.178.104 Boehringer Ingelheim Investigational Site
  • 9.178.095 Boehringer Ingelheim Investigational Site
  • 9.178.080 Boehringer Ingelheim Investigational Site
  • 9.178.139 Boehringer Ingelheim Investigational Site
  • 9.178.113 Boehringer Ingelheim Investigational Site
  • 9.178.115 Boehringer Ingelheim Investigational Site
  • 9.178.147 Boehringer Ingelheim Investigational Site
  • 9.178.092 Boehringer Ingelheim Investigational Site
  • 9.178.008 Boehringer Ingelheim Investigational Site
  • 9.178.035 Boehringer Ingelheim Investigational Site
  • 9.178.037 Boehringer Ingelheim Investigational Site
  • 9.178.051 Boehringer Ingelheim Investigational Site
  • 9.178.086 Boehringer Ingelheim Investigational Site
  • 9.178.162 Boehringer Ingelheim Investigational Site
  • 9.178.102 Boehringer Ingelheim Investigational Site
  • 9.178.023 Boehringer Ingelheim Investigational Site
  • 9.178.127 Boehringer Ingelheim Investigational Site
  • 9.178.004 Boehringer Ingelheim Investigational Site
  • 9.178.154 Boehringer Ingelheim Investigational Site
  • 9.178.155 Boehringer Ingelheim Investigational Site
  • 9.178.069 Boehringer Ingelheim Investigational Site
  • 9.178.070 Boehringer Ingelheim Investigational Site
  • 9.178.121 Boehringer Ingelheim Investigational Site
  • 9.178.141 Boehringer Ingelheim Investigational Site
  • 9.178.061 Boehringer Ingelheim Investigational Site
  • 9.178.085 Boehringer Ingelheim Investigational Site
  • 9.178.075 Boehringer Ingelheim Investigational Site
  • 9.178.107 Boehringer Ingelheim Investigational Site
  • 9.178.063 Boehringer Ingelheim Investigational Site
  • 9.178.083 Boehringer Ingelheim Investigational Site
  • 9.178.126 Boehringer Ingelheim Investigational Site
  • 9.178.150 Boehringer Ingelheim Investigational Site
  • 9.178.164 Boehringer Ingelheim Investigational Site
  • 9.178.015 Boehringer Ingelheim Investigational Site
  • 9.178.130 Boehringer Ingelheim Investigational Site
  • 9.178.057 Boehringer Ingelheim Investigational Site
  • 9.178.013 Boehringer Ingelheim Investigational Site
  • 9.178.043 Boehringer Ingelheim Investigational Site
  • 9.178.068 Boehringer Ingelheim Investigational Site
  • 9.178.116 Boehringer Ingelheim Investigational Site
  • 9.178.142 Boehringer Ingelheim Investigational Site
  • 9.178.078 Boehringer Ingelheim Investigational Site
  • 9.178.084 Boehringer Ingelheim Investigational Site
  • 9.178.009 Boehringer Ingelheim Investigational Site
  • 9.178.149 Boehringer Ingelheim Investigational Site
  • 9.178.071 Boehringer Ingelheim Investigational Site
  • 9.178.012 Boehringer Ingelheim Investigational Site
  • 9.178.100 Boehringer Ingelheim Investigational Site
  • 9.178.110 Boehringer Ingelheim Investigational Site
  • 9.178.020 Boehringer Ingelheim Investigational Site
  • 9.178.053 Boehringer Ingelheim Investigational Site
  • 9.178.132 Boehringer Ingelheim Investigational Site
  • 9.178.124 Boehringer Ingelheim Investigational Site
  • 9.178.158 Boehringer Ingelheim Investigational Site
  • 9.178.029 Boehringer Ingelheim Investigational Site
  • 9.178.096 Boehringer Ingelheim Investigational Site
  • 9.178.087 Boehringer Ingelheim Investigational Site
  • 9.178.058 Boehringer Ingelheim Investigational Site
  • 9.178.034 Boehringer Ingelheim Investigational Site
  • 9.178.157 Boehringer Ingelheim Investigational Site
  • 9.178.167 Boehringer Ingelheim Investigational Site
  • 9.178.137 Boehringer Ingelheim Investigational Site
  • 9.178.027 Boehringer Ingelheim Investigational Site
  • 9.178.073 Boehringer Ingelheim Investigational Site
  • 9.178.018 Boehringer Ingelheim Investigational Site
  • 9.178.160 Boehringer Ingelheim Investigational Site
  • 9.178.041 Boehringer Ingelheim Investigational Site
  • 9.178.088 Boehringer Ingelheim Investigational Site
  • 9.178.022 Boehringer Ingelheim Investigational Site
  • 9.178.076 Boehringer Ingelheim Investigational Site
  • 9.178.055 Boehringer Ingelheim Investigational Site
  • 9.178.111 Boehringer Ingelheim Investigational Site
  • 9.178.151 Boehringer Ingelheim Investigational Site
  • 9.178.156 Boehringer Ingelheim Investigational Site
  • 9.178.014 Boehringer Ingelheim Investigational Site
  • 9.178.039 Boehringer Ingelheim Investigational Site
  • 9.178.146 Boehringer Ingelheim Investigational Site
  • 9.178.144 Boehringer Ingelheim Investigational Site
  • 9.178.003 Boehringer Ingelheim Investigational Site
  • 9.178.040 Boehringer Ingelheim Investigational Site
  • 9.178.066 Boehringer Ingelheim Investigational Site
  • 9.178.134 Boehringer Ingelheim Investigational Site
  • 9.178.159 Boehringer Ingelheim Investigational Site
  • 9.178.007 Boehringer Ingelheim Investigational Site
  • 9.178.047 Boehringer Ingelheim Investigational Site
  • 9.178.090 Boehringer Ingelheim Investigational Site
  • 9.178.131 Boehringer Ingelheim Investigational Site
  • 9.178.006 Boehringer Ingelheim Investigational Site
  • 9.178.016 Boehringer Ingelheim Investigational Site
  • 9.178.091 Boehringer Ingelheim Investigational Site
  • 9.178.050 Boehringer Ingelheim Investigational Site
  • 9.178.106 Boehringer Ingelheim Investigational Site
  • 9.178.148 Boehringer Ingelheim Investigational Site
  • 9.178.114 Boehringer Ingelheim Investigational Site
  • 9.178.152 Boehringer Ingelheim Investigational Site
  • 9.178.125 Boehringer Ingelheim Investigational Site
  • 9.178.108 Boehringer Ingelheim Investigational Site
  • 9.178.103 Boehringer Ingelheim Investigational Site

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Other

Arm Label

Aggrenox Capsule

Acetylsalicylic Acid (ASA) 81 mg Tablet

Arm Description

Outcomes

Primary Outcome Measures

Number of Patients With First Recurrent Cerebral Infarction (Fatal or Non-fatal)
All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner.

Secondary Outcome Measures

Number of Patients With Brain (Cerebral) Haemorrhage
All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner.
Number of Patients With Subarachnoid Haemorrhage
All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner.
Number of Patients With Transient Ischemic Attack (TIA)
All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner.
Number of Patients With Acute Coronary Syndrome (ACS)
ACS contains acute myocardial infarction (MI), unstable angina and sudden cardiac death. All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner.
Number of Patients With Other Vascular Events
This endpoints were defined as pulmonary embolism, retinal vascular disorder, deep vein thrombosis, peripheral artery obstruction and vascular intervention. All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner.
Number of Patients With Ischemic Vascular Event Composite Endpoint
This is a composite endpoint of cerebral infarction, transient ischemic attack (TIA), acute myocardial infarction (MI), unstable angina and sudden death attributable to thromboembolism. All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner.

Full Information

First Posted
March 28, 2006
Last Updated
January 21, 2014
Sponsor
Boehringer Ingelheim
search

1. Study Identification

Unique Protocol Identification Number
NCT00311402
Brief Title
JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme
Official Title
JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme, Phase III Study to Compare the Preventive Effect of Recurrent Brain Infarction and Safety of Aggrenox (Combination Drug Containing Sustained-release Dipyridamole 200 mg/Acetylsalicylic Acid 25 mg) Twice Daily vs. Acetylsalicylic Acid 81 mg Once Daily
Study Type
Interventional

2. Study Status

Record Verification Date
January 2014
Overall Recruitment Status
Completed
Study Start Date
April 2006 (undefined)
Primary Completion Date
March 2009 (Actual)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Boehringer Ingelheim

4. Oversight

5. Study Description

Brief Summary
Phase III study to compare the preventive effect of recurrent brain infarction and safety of Aggrenox (combination drug containing sustained-release dipyridamole 200 mg/acetylsalicylic acid 25 mg) twice daily vs. acetylsalicylic acid 81 mg once daily

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cerebrovascular Accident

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Enrollment
1295 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Aggrenox Capsule
Arm Type
Other
Arm Title
Acetylsalicylic Acid (ASA) 81 mg Tablet
Arm Type
Other
Intervention Type
Drug
Intervention Name(s)
Aggrenox capsule
Intervention Description
extended-release dipyridamole 200 mg plus ASA 50 mg in a capsule, 2 capsules twice daily
Intervention Type
Other
Intervention Name(s)
Acetylsalicylic Acid (ASA)
Intervention Description
Acetylsalicylic Acid (ASA) 81 mg, 1 tablet once daily
Primary Outcome Measure Information:
Title
Number of Patients With First Recurrent Cerebral Infarction (Fatal or Non-fatal)
Description
All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner.
Time Frame
Up to 124 weeks
Secondary Outcome Measure Information:
Title
Number of Patients With Brain (Cerebral) Haemorrhage
Description
All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner.
Time Frame
Up to 124 weeks
Title
Number of Patients With Subarachnoid Haemorrhage
Description
All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner.
Time Frame
Up to 124 weeks
Title
Number of Patients With Transient Ischemic Attack (TIA)
Description
All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner.
Time Frame
Up to 124 weeks
Title
Number of Patients With Acute Coronary Syndrome (ACS)
Description
ACS contains acute myocardial infarction (MI), unstable angina and sudden cardiac death. All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner.
Time Frame
Up to 124 weeks
Title
Number of Patients With Other Vascular Events
Description
This endpoints were defined as pulmonary embolism, retinal vascular disorder, deep vein thrombosis, peripheral artery obstruction and vascular intervention. All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner.
Time Frame
Up to 124 weeks
Title
Number of Patients With Ischemic Vascular Event Composite Endpoint
Description
This is a composite endpoint of cerebral infarction, transient ischemic attack (TIA), acute myocardial infarction (MI), unstable angina and sudden death attributable to thromboembolism. All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner.
Time Frame
Up to 124 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with a diagnosis of cerebral infarction (excluding cardiogenic cerebral embolism) who meet the diagnostic criteria based on the National Institute of Neurological Disorders and Stroke (NINDS) ad hoc committee's classification of cerebrovascular disease III. Patients who have had an onset of cerebral infarction, the time of which is known, between 1 week and 6 months before the time of enrolment (including first and recurrent cerebral infarctions) Patients who are 50 years or older Patients whose neurological signs and symptoms are considered to be stable by the investigator or sub-investigator Patients with a finding corresponding to the responsible focus confirmed by head X-ray computerised tomography (CT) or magnetic resonance imaging (MRI) Patients who have at least two of the following risk factors: diabetes hypertension (systolic blood pressure is 140 mmHg or higher or diastolic blood pressure is 90 mmHg or higher) or under treatment of hypertension smoker (at the time of onset of cerebral infarction) obesity (Body mass index (BMI) is more than 25 kg/m2) previous vascular disease (stroke, acute myocardial infarction or peripheral arterial disease before the onset of cerebral infarction) end-organ damage (retinopathy, left ventricular hypertrophy (LVH) or microalbuminuria) hyperlipidaemia Exclusion Criteria: Patients with a diagnosis of brain disorders with a bleeding risk such as brain haemorrhage, subarachnoid haemorrhage, cerebral arteriovenous (AV) malformation, cerebral AV aneurysms and brain tumours Patients with complications of cardiac disorders (atrial fibrillation, mitral valve stenosis, severe cardiac valve disorders) that may provide an embolic source for cerebral embolism Patients having had acute coronary syndromes (acute myocardial infarction, unstable angina) within 6 months after enrolment in this study Patient with hypersensitivity to dipyridamole preparations Patients with a history of drug allergy to acetylsalicylic acid (ASA) or aspirin asthma Patients with a history of peptic ulcer Patients having undergone arterial reconstruction after development of cerebral infarction Patients with very severe impairment (4 or 5 on Modified Rankin Scale) Patients with bleeding or bleeding tendencies (haemophilia, haemorrhage urinary tract, vitreous haemorrhage, etc.) Patients with severe hypertension (systolic blood pressure is 180 mmHg or higher or diastolic blood pressure is 110 mmHg or higher) Patients with complications such as serious cardiac, renal and hepatic disorders Patients with a malignant tumour or having had a tumour treatment in the past 5 years Women who are or may be pregnant or lactating women
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Boehringer Ingelheim
Organizational Affiliation
Boehringer Ingelheim
Official's Role
Study Chair
Facility Information:
Facility Name
9.178.060 Boehringer Ingelheim Investigational Site
City
Adachi-ku, Tokyo
Country
Japan
Facility Name
9.178.017 Boehringer Ingelheim Investigational Site
City
Adumino, Nagano
Country
Japan
Facility Name
9.178.032 Boehringer Ingelheim Investigational Site
City
Akashi, Hyogo
Country
Japan
Facility Name
9.178.074 Boehringer Ingelheim Investigational Site
City
Akashi, Hyogo
Country
Japan
Facility Name
9.178.062 Boehringer Ingelheim Investigational Site
City
Ako, Hyogo
Country
Japan
Facility Name
9.178.064 Boehringer Ingelheim Investigational Site
City
Aoba-ku, Yokohama, Kanagawa
Country
Japan
Facility Name
9.178.097 Boehringer Ingelheim Investigational Site
City
Aoi-ku, Shizuoka, Shizuoka
Country
Japan
Facility Name
9.178.056 Boehringer Ingelheim Investigational Site
City
Asahi, Chiba
Country
Japan
Facility Name
9.178.067 Boehringer Ingelheim Investigational Site
City
Asahikawa, Hokkaido
Country
Japan
Facility Name
9.178.117 Boehringer Ingelheim Investigational Site
City
Asahikawa, Hokkaido
Country
Japan
Facility Name
9.178.166 Boehringer Ingelheim Investigational Site
City
Atsugi, Kanagawa
Country
Japan
Facility Name
9.178.089 Boehringer Ingelheim Investigational Site
City
Bunkyo-ku, Tokyo
Country
Japan
Facility Name
9.178.054 Boehringer Ingelheim Investigational Site
City
Chitose, Hokkaido
Country
Japan
Facility Name
9.178.133 Boehringer Ingelheim Investigational Site
City
Chuo-ku, Chiba, Chiba
Country
Japan
Facility Name
9.178.030 Boehringer Ingelheim Investigational Site
City
Chuo-ku, Kobe, Hyogo
Country
Japan
Facility Name
9.178.077 Boehringer Ingelheim Investigational Site
City
Chuo-ku, Sapporo, Hokkaido
Country
Japan
Facility Name
9.178.002 Boehringer Ingelheim Investigational Site
City
Chuo-Ku, Sappro, Hokkaido
Country
Japan
Facility Name
9.178.119 Boehringer Ingelheim Investigational Site
City
Chuo-ku, Sappro, Hokkaido
Country
Japan
Facility Name
9.178.161 Boehringer Ingelheim Investigational Site
City
Daito, Osaka
Country
Japan
Facility Name
9.178.112 Boehringer Ingelheim Investigational Site
City
Fuchu, Tokyo
Country
Japan
Facility Name
9.178.098 Boehringer Ingelheim Investigational Site
City
Fujieda, Shizuoka
Country
Japan
Facility Name
9.178.046 Boehringer Ingelheim Investigational Site
City
Fukaya, Saitama
Country
Japan
Facility Name
9.178.145 Boehringer Ingelheim Investigational Site
City
Fukui, Fukui
Country
Japan
Facility Name
9.178.099 Boehringer Ingelheim Investigational Site
City
Fukuroi, Shizuoka
Country
Japan
Facility Name
9.178.165 Boehringer Ingelheim Investigational Site
City
Funabashi, Chiba
Country
Japan
Facility Name
9.178.072 Boehringer Ingelheim Investigational Site
City
Fushimi-ku, Kyoto, Kyoto
Country
Japan
Facility Name
9.178.081 Boehringer Ingelheim Investigational Site
City
Gifu, Gifu
Country
Japan
Facility Name
9.178.024 Boehringer Ingelheim Investigational Site
City
Habikino, Osaka
Country
Japan
Facility Name
9.178.136 Boehringer Ingelheim Investigational Site
City
Hachioji, Tokyo
Country
Japan
Facility Name
9.178.082 Boehringer Ingelheim Investigational Site
City
Hakodate, Hokkaido
Country
Japan
Facility Name
9.178.118 Boehringer Ingelheim Investigational Site
City
Hakodate, Hokkaido
Country
Japan
Facility Name
9.178.052 Boehringer Ingelheim Investigational Site
City
Hamada, Shimane
Country
Japan
Facility Name
9.178.138 Boehringer Ingelheim Investigational Site
City
Hashima-gun, Gifu
Country
Japan
Facility Name
9.178.169 Boehringer Ingelheim Investigational Site
City
Hidaka, Saitama
Country
Japan
Facility Name
9.178.001 Boehringer Ingelheim Investigational Site
City
Higashi-ku, Sappro, Hokkaido
Country
Japan
Facility Name
9.178.026 Boehringer Ingelheim Investigational Site
City
Higashi-osaka, Osaka
Country
Japan
Facility Name
9.178.163 Boehringer Ingelheim Investigational Site
City
Higashidakawa-gun, Yamagata
Country
Japan
Facility Name
9.178.120 Boehringer Ingelheim Investigational Site
City
Higashimatsushima, Miyagi
Country
Japan
Facility Name
9.178.028 Boehringer Ingelheim Investigational Site
City
Higashinari-ku, Osaka, Osaka
Country
Japan
Facility Name
9.178.140 Boehringer Ingelheim Investigational Site
City
Higashiosaka, Osaka
Country
Japan
Facility Name
9.178.122 Boehringer Ingelheim Investigational Site
City
Higashisonogi-gun, Nagasaki
Country
Japan
Facility Name
9.178.101 Boehringer Ingelheim Investigational Site
City
Higashiyodogawa-ku, Osaka, Osaka
Country
Japan
Facility Name
9.178.093 Boehringer Ingelheim Investigational Site
City
Himeji, Hyogo
Country
Japan
Facility Name
9.178.153 Boehringer Ingelheim Investigational Site
City
Hitachi, Ibaraki
Country
Japan
Facility Name
9.178.005 Boehringer Ingelheim Investigational Site
City
Hitachinaka, Ibaraki
Country
Japan
Facility Name
9.178.079 Boehringer Ingelheim Investigational Site
City
Ibusuki, Kagoshima
Country
Japan
Facility Name
9.178.143 Boehringer Ingelheim Investigational Site
City
Ichikawa, Chiba
Country
Japan
Facility Name
9.178.019 Boehringer Ingelheim Investigational Site
City
Iida, Nagano
Country
Japan
Facility Name
9.178.129 Boehringer Ingelheim Investigational Site
City
Inashiki-gun, Ibaraki
Country
Japan
Facility Name
9.178.011 Boehringer Ingelheim Investigational Site
City
Isesaki, Gunma
Country
Japan
Facility Name
9.178.045 Boehringer Ingelheim Investigational Site
City
Isesaki, Gunma
Country
Japan
Facility Name
9.178.031 Boehringer Ingelheim Investigational Site
City
Itami, Hyogo
Country
Japan
Facility Name
9.178.135 Boehringer Ingelheim Investigational Site
City
Iwanuma, Miyagi
Country
Japan
Facility Name
9.178.104 Boehringer Ingelheim Investigational Site
City
Iwata, Shizuoka
Country
Japan
Facility Name
9.178.095 Boehringer Ingelheim Investigational Site
City
Izuka, Fukuoka
Country
Japan
Facility Name
9.178.080 Boehringer Ingelheim Investigational Site
City
Izumisano, Osaka
Country
Japan
Facility Name
9.178.139 Boehringer Ingelheim Investigational Site
City
Izumo, Shimane
Country
Japan
Facility Name
9.178.113 Boehringer Ingelheim Investigational Site
City
Izunokuni, Shizuoka
Country
Japan
Facility Name
9.178.115 Boehringer Ingelheim Investigational Site
City
Kahoku-gun, Ishikawa
Country
Japan
Facility Name
9.178.147 Boehringer Ingelheim Investigational Site
City
Kameda-gun, Hokkaido
Country
Japan
Facility Name
9.178.092 Boehringer Ingelheim Investigational Site
City
Kamigyo-ku, Kyoto, Kyoto
Country
Japan
Facility Name
9.178.008 Boehringer Ingelheim Investigational Site
City
Kasama, Ibaraki
Country
Japan
Facility Name
9.178.035 Boehringer Ingelheim Investigational Site
City
Kasuga, Fukuoka
Country
Japan
Facility Name
9.178.037 Boehringer Ingelheim Investigational Site
City
Kasuga, Fukuoka
Country
Japan
Facility Name
9.178.051 Boehringer Ingelheim Investigational Site
City
Kawachinagano, Osaka
Country
Japan
Facility Name
9.178.086 Boehringer Ingelheim Investigational Site
City
Kisarazu, Chiba
Country
Japan
Facility Name
9.178.162 Boehringer Ingelheim Investigational Site
City
Kishiwada, Osaka
Country
Japan
Facility Name
9.178.102 Boehringer Ingelheim Investigational Site
City
Kita-ku, Nagoya, Aichi
Country
Japan
Facility Name
9.178.023 Boehringer Ingelheim Investigational Site
City
Kita-ku, Osaka, Osaka
Country
Japan
Facility Name
9.178.127 Boehringer Ingelheim Investigational Site
City
Kita-ku, Osaka, Osaka
Country
Japan
Facility Name
9.178.004 Boehringer Ingelheim Investigational Site
City
Kita-ku, Sappro, Hokkaido
Country
Japan
Facility Name
9.178.154 Boehringer Ingelheim Investigational Site
City
Kitami, Hokkaido
Country
Japan
Facility Name
9.178.155 Boehringer Ingelheim Investigational Site
City
Kitami, Hokkaido
Country
Japan
Facility Name
9.178.069 Boehringer Ingelheim Investigational Site
City
Kiyose, Tokyo
Country
Japan
Facility Name
9.178.070 Boehringer Ingelheim Investigational Site
City
Kiyose, Tokyo
Country
Japan
Facility Name
9.178.121 Boehringer Ingelheim Investigational Site
City
Kochi, Kochi
Country
Japan
Facility Name
9.178.141 Boehringer Ingelheim Investigational Site
City
Kochi, Kochi
Country
Japan
Facility Name
9.178.061 Boehringer Ingelheim Investigational Site
City
Koriyama, Fukushima
Country
Japan
Facility Name
9.178.085 Boehringer Ingelheim Investigational Site
City
Koriyama, Fukushima
Country
Japan
Facility Name
9.178.075 Boehringer Ingelheim Investigational Site
City
Koshi, Kumamoto
Country
Japan
Facility Name
9.178.107 Boehringer Ingelheim Investigational Site
City
Kurashiki, Okayama
Country
Japan
Facility Name
9.178.063 Boehringer Ingelheim Investigational Site
City
Kushiro, Hokkaido
Country
Japan
Facility Name
9.178.083 Boehringer Ingelheim Investigational Site
City
Kushiro, Hokkaido
Country
Japan
Facility Name
9.178.126 Boehringer Ingelheim Investigational Site
City
Kushiro, Hokkaido
Country
Japan
Facility Name
9.178.150 Boehringer Ingelheim Investigational Site
City
Marugame, Kagawa
Country
Japan
Facility Name
9.178.164 Boehringer Ingelheim Investigational Site
City
Matsudo, Chiba
Country
Japan
Facility Name
9.178.015 Boehringer Ingelheim Investigational Site
City
Matsumoto, Nagano
Country
Japan
Facility Name
9.178.130 Boehringer Ingelheim Investigational Site
City
Meguro-ku, Tokyo
Country
Japan
Facility Name
9.178.057 Boehringer Ingelheim Investigational Site
City
Meito-ku, Nagoya, Aichi
Country
Japan
Facility Name
9.178.013 Boehringer Ingelheim Investigational Site
City
Midori-ku, Yokohama, Kanagawa
Country
Japan
Facility Name
9.178.043 Boehringer Ingelheim Investigational Site
City
Minami-ku, Hiroshima, Hiroshima
Country
Japan
Facility Name
9.178.068 Boehringer Ingelheim Investigational Site
City
Miyagino-ku, Sendai, Miyagi
Country
Japan
Facility Name
9.178.116 Boehringer Ingelheim Investigational Site
City
Miyazaki, Miyazaki
Country
Japan
Facility Name
9.178.142 Boehringer Ingelheim Investigational Site
City
Moriguchi, Osaka
Country
Japan
Facility Name
9.178.078 Boehringer Ingelheim Investigational Site
City
Morioka, Iwate
Country
Japan
Facility Name
9.178.084 Boehringer Ingelheim Investigational Site
City
Morioka, Iwate
Country
Japan
Facility Name
9.178.009 Boehringer Ingelheim Investigational Site
City
Moriya, Ibaraki
Country
Japan
Facility Name
9.178.149 Boehringer Ingelheim Investigational Site
City
Moriya, Ibaraki
Country
Japan
Facility Name
9.178.071 Boehringer Ingelheim Investigational Site
City
Musashimurayama, Tokyo
Country
Japan
Facility Name
9.178.012 Boehringer Ingelheim Investigational Site
City
Musashino, Tokyo
Country
Japan
Facility Name
9.178.100 Boehringer Ingelheim Investigational Site
City
Naka-ku, Hamamatsu, Shizuoka
Country
Japan
Facility Name
9.178.110 Boehringer Ingelheim Investigational Site
City
Naka-ku, Hamamatsu, Shizuoka
Country
Japan
Facility Name
9.178.020 Boehringer Ingelheim Investigational Site
City
Naka-ku, Nagoya, Aichi
Country
Japan
Facility Name
9.178.053 Boehringer Ingelheim Investigational Site
City
Nakagawa-ku, Nagoya, Aichi
Country
Japan
Facility Name
9.178.132 Boehringer Ingelheim Investigational Site
City
Nakagawa-ku, Nagoya, Nagoya
Country
Japan
Facility Name
9.178.124 Boehringer Ingelheim Investigational Site
City
Namegata, Ibaraki
Country
Japan
Facility Name
9.178.158 Boehringer Ingelheim Investigational Site
City
Nanao, Ishikawa
Country
Japan
Facility Name
9.178.029 Boehringer Ingelheim Investigational Site
City
Nishi-yodogawa-ku, Osaka, Osaka
Country
Japan
Facility Name
9.178.096 Boehringer Ingelheim Investigational Site
City
Nishisonogi-gun, Nagasaki
Country
Japan
Facility Name
9.178.087 Boehringer Ingelheim Investigational Site
City
Noda, Chiba
Country
Japan
Facility Name
9.178.058 Boehringer Ingelheim Investigational Site
City
Obu, Aichi
Country
Japan
Facility Name
9.178.034 Boehringer Ingelheim Investigational Site
City
Ohnojo, Fukuoka
Country
Japan
Facility Name
9.178.157 Boehringer Ingelheim Investigational Site
City
Okayama, Okayama
Country
Japan
Facility Name
9.178.167 Boehringer Ingelheim Investigational Site
City
Okinawa, Okinawa
Country
Japan
Facility Name
9.178.137 Boehringer Ingelheim Investigational Site
City
Sagamihara, Kanagawa
Country
Japan
Facility Name
9.178.027 Boehringer Ingelheim Investigational Site
City
Sakai, Osaka
Country
Japan
Facility Name
9.178.073 Boehringer Ingelheim Investigational Site
City
Sakai, Osaka
Country
Japan
Facility Name
9.178.018 Boehringer Ingelheim Investigational Site
City
Saku, Nagano
Country
Japan
Facility Name
9.178.160 Boehringer Ingelheim Investigational Site
City
Sapporo, Hokkaido
Country
Japan
Facility Name
9.178.041 Boehringer Ingelheim Investigational Site
City
Setagaya-ku, Tokyo
Country
Japan
Facility Name
9.178.088 Boehringer Ingelheim Investigational Site
City
Shibuya-ku, Tokyo
Country
Japan
Facility Name
9.178.022 Boehringer Ingelheim Investigational Site
City
Shimogyo-ku, Kyoto, Kyoto
Country
Japan
Facility Name
9.178.076 Boehringer Ingelheim Investigational Site
City
Shimotsuke, Tochigi
Country
Japan
Facility Name
9.178.055 Boehringer Ingelheim Investigational Site
City
Shiroishi, Miyagi
Country
Japan
Facility Name
9.178.111 Boehringer Ingelheim Investigational Site
City
Simizu-ku, Shizuoka, Shizuoka
Country
Japan
Facility Name
9.178.151 Boehringer Ingelheim Investigational Site
City
Suminoe-ku, Osaka, Osaka
Country
Japan
Facility Name
9.178.156 Boehringer Ingelheim Investigational Site
City
Susono, Shizuoka
Country
Japan
Facility Name
9.178.014 Boehringer Ingelheim Investigational Site
City
Suwa, Nagano
Country
Japan
Facility Name
9.178.039 Boehringer Ingelheim Investigational Site
City
Takasaki, Gunma
Country
Japan
Facility Name
9.178.146 Boehringer Ingelheim Investigational Site
City
Takatsuki, Osaka
Country
Japan
Facility Name
9.178.144 Boehringer Ingelheim Investigational Site
City
Takayama, Gifu
Country
Japan
Facility Name
9.178.003 Boehringer Ingelheim Investigational Site
City
Takikawa, Hokkaido
Country
Japan
Facility Name
9.178.040 Boehringer Ingelheim Investigational Site
City
Tatebayashi, Gunma
Country
Japan
Facility Name
9.178.066 Boehringer Ingelheim Investigational Site
City
Teine-ku, Sapporo, Hokkaido
Country
Japan
Facility Name
9.178.134 Boehringer Ingelheim Investigational Site
City
Tenri, Nara
Country
Japan
Facility Name
9.178.159 Boehringer Ingelheim Investigational Site
City
Tonami, Toyama
Country
Japan
Facility Name
9.178.007 Boehringer Ingelheim Investigational Site
City
Toride, Ibaraki
Country
Japan
Facility Name
9.178.047 Boehringer Ingelheim Investigational Site
City
Toyama, Toyama
Country
Japan
Facility Name
9.178.090 Boehringer Ingelheim Investigational Site
City
Toyohashi, Aichi
Country
Japan
Facility Name
9.178.131 Boehringer Ingelheim Investigational Site
City
Toyota, Aichi
Country
Japan
Facility Name
9.178.006 Boehringer Ingelheim Investigational Site
City
Tsuchiura, Ibaraki
Country
Japan
Facility Name
9.178.016 Boehringer Ingelheim Investigational Site
City
Ueda, Nagano
Country
Japan
Facility Name
9.178.091 Boehringer Ingelheim Investigational Site
City
Uji, Kyoto
Country
Japan
Facility Name
9.178.050 Boehringer Ingelheim Investigational Site
City
Ukyo-ku, Kyoto, Kyoto
Country
Japan
Facility Name
9.178.106 Boehringer Ingelheim Investigational Site
City
Urayasu, Chiba
Country
Japan
Facility Name
9.178.148 Boehringer Ingelheim Investigational Site
City
Wakayama, Wakayama
Country
Japan
Facility Name
9.178.114 Boehringer Ingelheim Investigational Site
City
Wko, Saitama
Country
Japan
Facility Name
9.178.152 Boehringer Ingelheim Investigational Site
City
Yaizu, Shizuoka
Country
Japan
Facility Name
9.178.125 Boehringer Ingelheim Investigational Site
City
Yamashina, Kyoto, Kyoto
Country
Japan
Facility Name
9.178.108 Boehringer Ingelheim Investigational Site
City
Yanai, Yamaguchi
Country
Japan
Facility Name
9.178.103 Boehringer Ingelheim Investigational Site
City
Yao, Osaka
Country
Japan

12. IPD Sharing Statement

Citations:
PubMed Identifier
21502757
Citation
Uchiyama S, Ikeda Y, Urano Y, Horie Y, Yamaguchi T. The Japanese aggrenox (extended-release dipyridamole plus aspirin) stroke prevention versus aspirin programme (JASAP) study: a randomized, double-blind, controlled trial. Cerebrovasc Dis. 2011;31(6):601-13. doi: 10.1159/000327035. Epub 2011 Apr 19.
Results Reference
derived
Links:
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/9/9.178_U09-2224-02.pdf
Description
Related Info
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/9/9.178_literature.pdf
Description
Related Info

Learn more about this trial

JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme

We'll reach out to this number within 24 hrs